Pangen Biotech팬젠
222110 · KOSDAQ · ₩222110 · 팬젠
₩4,640▲ ₩60 (1.31%)End-of-day · Oct 28, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 28.2% | 33.6% | 35.1% | 13.5% | 10.2% | 6.7% |
| Operating margin | 1.7% | 11.2% | 7.0% | −57.8% | −70.6% | −41.4% |
| Net margin | 8.0% | 15.3% | 6.4% | −61.4% | −69.1% | −41.7% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +5.7% | −8.6% | +100.6% | +12.5% | −18.1% | — |
| Operating income growth | −84.4% | +47.6% | +124.1% | +8.0% | −39.6% | — |
| Net income growth | −44.8% | +117.3% | +121.0% | +0.1% | −35.8% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | 3.7% | 7.5% | 5.0% | −30.1% | −23.5% | −15.7% |
| Return on assets | 3.4% | 6.5% | 3.7% | −21.7% | −14.1% | −7.6% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 8.2% | 9.3% | 22.6% | 65.1% | 20.1% | 105.1% |
| Net debt to equity | −9.8% | −9.3% | −2.5% | 15.7% | −5.2% | 46.4% |
| Current ratio | 955.0% | 842.6% | 716.4% | 172.4% | 759.3% | 156.7% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Pangen Biotech / 팬젠 / 222110 / KRX:222110
Source: KRX statistical information